Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
